Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,218 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF.
Cunningham JW, Claggett BL, O'Meara E, Prescott MF, Pfeffer MA, Shah SJ, Redfield MM, Zannad F, Chiang LM, Rizkala AR, Shi VC, Lefkowitz MP, Rouleau J, McMurray JJV, Solomon SD, Zile MR. Cunningham JW, et al. Among authors: zannad f. J Am Coll Cardiol. 2020 Aug 4;76(5):503-514. doi: 10.1016/j.jacc.2020.05.072. J Am Coll Cardiol. 2020. PMID: 32731928 Free article. Clinical Trial.
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD, Aylward PE, Huang Z, Dalby AJ, Weaver WD, Barvik S, Marin-Neto JA, Murin J, Nordlander RO, van Gilst WH, Zannad F, McMurray JJ, Califf RM, Pfeffer MA; VALIANT Investigators. White HD, et al. Among authors: zannad f. Circulation. 2005 Nov 29;112(22):3391-9. doi: 10.1161/CIRCULATIONAHA.105.551143. Epub 2005 Nov 21. Circulation. 2005. PMID: 16301343 Clinical Trial.
Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction.
Køber L, Swedberg K, McMurray JJ, Pfeffer MA, Velazquez EJ, Diaz R, Maggioni AP, Mareev V, Opolski G, Van de Werf F, Zannad F, Ertl G, Solomon SD, Zelenkofske S, Rouleau JL, Leimberger JD, Califf RM. Køber L, et al. Among authors: zannad f. Eur J Heart Fail. 2006 Oct;8(6):591-8. doi: 10.1016/j.ejheart.2005.11.007. Epub 2006 Feb 28. Eur J Heart Fail. 2006. PMID: 16507350 Free article. Clinical Trial.
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B. Rajagopalan S, et al. Among authors: zannad f. Am J Cardiol. 2007 Jul 15;100(2):222-6. doi: 10.1016/j.amjcard.2007.02.085. Epub 2007 May 30. Am J Cardiol. 2007. PMID: 17631074 Clinical Trial.
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study.
Lewis EF, Velazquez EJ, Solomon SD, Hellkamp AS, McMurray JJ, Mathias J, Rouleau JL, Maggioni AP, Swedberg K, Kober L, White H, Dalby AJ, Francis GS, Zannad F, Califf RM, Pfeffer MA. Lewis EF, et al. Among authors: zannad f. Eur Heart J. 2008 Mar;29(6):748-56. doi: 10.1093/eurheartj/ehn062. Epub 2008 Feb 28. Eur Heart J. 2008. PMID: 18308687 Clinical Trial.
Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.
Radauceanu A, Ducki C, Virion JM, Rossignol P, Mallat Z, McMurray J, Van Veldhuisen DJ, Tavazzi L, Mann DL, Capiaumont-Vin J, Li M, Hanriot D, Zannad F. Radauceanu A, et al. Among authors: zannad f. J Card Fail. 2008 Aug;14(6):467-74. doi: 10.1016/j.cardfail.2008.02.014. Epub 2008 May 27. J Card Fail. 2008. PMID: 18672194 Clinical Trial.
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: zannad f. J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056. J Am Coll Cardiol. 2008. PMID: 18992654 Free article. Clinical Trial.
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group.
Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N; Acute Heart Failure Syndromes International Working Group. Gheorghiade M, et al. Among authors: zannad f. Am Heart J. 2009 Jun;157(6):957-70. doi: 10.1016/j.ahj.2009.04.010. Am Heart J. 2009. PMID: 19464405 No abstract available.
1,218 results